» Articles » PMID: 15192072

Recombinant Human LH Supplementation During GnRH Antagonist Administration in IVF/ICSI Cycles: a Prospective Randomized Study

Overview
Journal Hum Reprod
Date 2004 Jun 12
PMID 15192072
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Background: When administered in the late follicular phase to prevent an LH surge, GnRH antagonists induce a sharp decrease in serum LH levels that may be detrimental for assisted reproductive technology cycle outcome. Therefore, a prospective study was designed to assess the effects of recombinant human (r)LH supplementation during GnRH antagonist (cetrorelix) administration.

Methods: The protocol consisted of cycle programming with oral contraceptive pill, ovarian stimulation with rFSH and flexible administration of a single dose of cetrorelix (3 mg). A total of 218 patients from three IVF centres were randomized (by sealed envelopes or according to woman's birth date) to receive (n = 114) or not (n = 104) a daily injection of rLH 75 IU from GnRH antagonist initiation to hCG injection.

Results: The only significant difference was a higher serum peak E2 level in patients treated with rLH (1476 +/- 787 versus 1012 +/- 659 pg/ml, P < 0.001) whereas the numbers of oocytes and embryos as well as the delivery rate (25.2 versus 24%) and the implantation rate per embryo (19.1 versus 17.4%) were similar in both groups.

Conclusions: These results show that in an unselected group of patients, there is no evident benefit to supplement GnRH antagonist-treated cycles with rLH.

Citing Articles

Recombinant human luteinizing hormone increases endometrial thickness in women undergoing assisted fertility treatments: a systematic review and meta-analysis.

Mao R, Hou X, Feng X, Wang R, Fei X, Zhao J Front Pharmacol. 2024; 15:1434625.

PMID: 39135787 PMC: 11317380. DOI: 10.3389/fphar.2024.1434625.


Role of luteinizing hormone elevation in outcomes of ovulation induction with letrozole for polycystic ovary syndrome.

Fu W, Kuang Y Front Med (Lausanne). 2023; 10:1113840.

PMID: 37144035 PMC: 10151707. DOI: 10.3389/fmed.2023.1113840.


Luteinizing hormone supplementation in women with hypogonadotropic hypogonadism seeking fertility care: Insights from a narrative review.

Di Segni N, Busnelli A, Secchi M, Cirillo F, Levi-Setti P Front Endocrinol (Lausanne). 2022; 13:907249.

PMID: 35979440 PMC: 9377693. DOI: 10.3389/fendo.2022.907249.


Recombinant LH supplementation improves cumulative live birth rates in the GnRH antagonist protocol: a multicenter retrospective study using a propensity score-matching analysis.

Wang M, Huang R, Liang X, Mao Y, Shi W, Li Q Reprod Biol Endocrinol. 2022; 20(1):114.

PMID: 35941630 PMC: 9358814. DOI: 10.1186/s12958-022-00985-4.


Improving Implantation Rate in 2nd ICSI Cycle through Ovarian Stimulation with FSH and LH in GNRH Antagonist Regimen.

Setti A, Braga D, Iaconelli Junior A, Borges Junior E Rev Bras Ginecol Obstet. 2021; 43(10):749-758.

PMID: 34784631 PMC: 10183840. DOI: 10.1055/s-0041-1736306.